TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33357070
Drug: Taurine (50 mg·kg‐1)
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine (50 mg·kg‐1)
Study: 33610734
Drug: zolbetuximab +
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolbetuximab + EOX (800 mg/m2 loading dose, then 600 mg/m2 Q3W)
Study: 33610734
Drug: zolbetuximab +
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolbetuximab + EOX (1000 mg/m2 Q3W)
Study: 32120445
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion administered immediately after incision of the visceral peritoneum (Group I)
Study: 32120445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Oxytocin infusion administered immediately after clamping the umbilical cord, Group II)
Study: 32120445
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (Group I)
Study: 34496448
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg esketamine (SK0)
Study: 32408905
Drug: Anthracycline-free chemotherapy
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-free chemotherapy regimen (6x docetaxel/cyclophosphamide, TC)
Study: 35400202
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic BP 110-139 mm Hg)
Study: 39696255
Drug: Daily coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily coffee consumption
Study: 36333773
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) plus metformin
Study: 36333773
Drug: Levonorgestrel-releasing intrauterine
Normalized name: levonorgestrel Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin
Study: 35660972
Drug: Pembrolizumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab and chemotherapy
Study: 33386288
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy with planning based on prostate-specific membrane antigen positron emission tomography/computed tomography
Study: 33386288
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy without planning based on prostate-specific membrane antigen positron emission tomography/computed tomography
Study: 32673830
Drug: Accelerated antibiotic
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated antibiotic treatment (2 to 4 weeks)
Study: 32673830
Drug: Standard‐length antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐length antibiotic treatment (4 to 6 weeks)
Study: 34029682
Drug: Oral ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ferric maltol at 30mg twice daily for 16 weeks
Study: 34029682
Drug: Oral ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ferric maltol at 30mg twice daily (continued treatment)
Study: 33989641
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol
Study: 35120149
Drug: Neural mobilisation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neural mobilisation techniques and soft tissue mobilisation techniques for 30 minutes per session, 10 weekly sessions, plus advice to stay active on their activities of daily living, information on physical activity, imaging tests, and sciatica for 5 biweekly sessions lasting 25‐30 minutes.
Study: 32520870
Drug: Moderate-intensity walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity walking (low dose: 33.6 kJ·kg body weight per week)
Study: 32520870
Drug: Moderate-intensity walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity walking (moderate dose: 58.8 kJ·kg body weight per week)
Study: 32520870
Drug: Moderate-intensity walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity walking (moderate dose)
Study: 32520870
Drug: Moderate-intensity walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity walking (low dose)
Study: 36444207
Drug: Dexamethasone 0.4
Normalized name: dexamethasone 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.4 mg intracanalicular insert (DEX)
Study: 36444207
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate (PRED)
Study: 32634360
Drug: Earned Income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earned Income Tax Credit of up to $2,000 (treatment)
Study: 34519136
Drug: Aspirin, paracetamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, paracetamol, and caffeine (APC)
Study: 32960242
Drug: Prophylactic negative
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic negative pressure wound therapy
Study: 36501066
Drug: Citrulline 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline 3 g
Study: 33630662
Drug: Combined memory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined memory treatment (traditional episodic memory therapy + semantic memory-focused therapy)
Study: 35448469
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g whey protein + 10 g sucrose (W‐S‐group)
Study: 35448469
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g whey protein (W‐group)
Study: 34610541
Drug: Preoperative methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative methylprednisolone (40 mg or 120 mg)
Study: 32272030
Drug: Guideline-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based physical therapy plus dry needling
Study: 32272030
Drug: Guideline-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based physical therapy
Study: 34157188
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet therapy (EDT) using an amino acid‐based formula
Study: 35830201
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus arbidol tablets (200 mg three times a day for 14 days)
Study: 35830201
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus arbidol tablets
Study: 32048107
Drug: bezlotoxumab 10
Normalized name: bezlotoxumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezlotoxumab 10 mg/kg
Study: 33180100
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy regimen of 36 Gy in once-daily 2-Gy fractions
Study: 39520655
Drug: Cariprazine 1.5
Normalized name: cariprazine 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 1.5 mg/day
Study: 39520655
Drug: Cariprazine 3
Normalized name: cariprazine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3 mg/day
Study: 35836691
Drug: Increased raw
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased raw vegetable intake through seminars and intensive coaching weekly
Study: 34784301
Drug: Dialysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis treatment
Study: 35876109
Drug: 2,4-D herbicide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,4-D herbicide at a dose of 2.04 g a.e. ha-1
Study: 35876109
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of 2,4-D applied at tillering stage
Study: 35876109
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of 2,4-D
Study: 34333788
Drug: Intragastric balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric balloon therapy
Study: 32873473
Drug: Ceftriaxone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone monotherapy
Study: 36202942
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid pulse therapy
Study: 32651286
Drug: Laquinimod 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 1.5 mg
Study: 35491679
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg oral dose
Study: 33884609
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (SS) in PR group
Study: 33884609
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 mcg/kg/h) in substudy 2
Study: 33884609
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (SS) in substudy 2
Study: 32739974
Drug: Valaciclovir at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir at a dose of 8g/day
Study: 33367869
Drug: Cholecalciferol 3000
Normalized name: Cholecalciferol 3000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 3000 IU daily
Study: 33367869
Drug: Cholecalciferol 25,000
Normalized name: CHOLECALCIFEROL 25,000UNIT CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 25,000 IU weekly
Study: 33367869
Drug: Cholecalciferol 100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 100,000 IU monthly
Study: 33367869
Drug: Cholecalciferol 1000
Normalized name: cholecalciferol 1000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1000 IU daily (maintenance course)
Study: 32563846
Drug: Buprenorphine-naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone treatment
Study: 34724895
Drug: Medication reviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reviews during hospitalisation
Study: 34672898
Drug: Cangrelor (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor (intravenous P2Y12 receptor antagonist) as a bridging therapy
Study: 32959922
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rivaroxaban
Study: 35930750
Drug: Vemurafenib monotherapy
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib monotherapy
Study: 34872568
Drug: Gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐releasing hormone agonist (GnRHa)
Study: 35417485
Drug: Monthly issue-focused
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly issue-focused counseling (for non-responders)
Study: 33199423
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement containing 0.8 mg of folic acid
Study: 33199423
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement without folic acid
Study: 34411291
Drug: Nd:YAG laser-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser-assisted periodontal therapy (3 W, 100 μs, 20 Hz; 4 W, 600 μs, 20 Hz)
Study: 36314174
Drug: Intranasal GM‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GM‐CSF administration
Study: 33032885
Drug: Finger Kazoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finger Kazoo Intensive Short-Term Vocal Therapy
Study: 35871638
Drug: Low-dose endotoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose endotoxin (0.8 ng/kg of body weight)
Study: 35005013
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine
Study: 36317757
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (trastuzumab)
Study: 36317757
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (biosimilar)
Study: 34880026
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) - seven sessions focused on expectancy management, cognitions regarding pain, and emotional and behavioural impact of pain
Study: 34611418
Drug: Super bioavailable
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super bioavailable itraconazole (SBITZ) capsules
Study: 34611418
Drug: Conventional itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional itraconazole (CITZ) capsules
Study: 32512782
Drug: Longvida© (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longvida© (400 mg daily containing 80 mg curcumin)
Study: 34125632
Drug: Both tablets
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tablets
Study: 35691326
Drug: Short treatment
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short treatment group
Study: 33140267
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser (810 nm, 1.0 W, CW, irradiation time 20 s for 3 applications) once daily for 3 days
Study: 33325562
Drug: Acarbose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (1 x 50 mg, 2 x 50 mg, 3 x 50 mg)
Study: 34988583
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) - 3 sessions per week, parent-led, infant-directed singing supported by a music therapist; mean of 10 sessions (SD 5.95), with 83% receiving at least 6 sessions.
Study: 34988583
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) - 3 sessions per week, parent-led, infant-directed singing supported by a music therapist.
Study: 34988583
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care (C) - control group receiving usual care without music therapy.
Study: 34554243
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 or 300 mg every 4 or 8 weeks
Study: 32264919
Drug: Upfront radical
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront radical surgery with total mesorectal excision (TME) followed by adjuvant FOLFOX chemotherapy
Study: 32264919
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy (PCRT) followed by TME and adjuvant chemotherapy
Study: 33796907
Drug: IV nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV nicotine (0.0125, 0.025, 0.05, 0.1, or 0.2 mg nicotine/70 kg bodyweight)
Study: 35254839
Drug: IV nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV nicotine (0.2 mg)
Study: 32944971
Drug: Group acceptance
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group acceptance and commitment therapy for Psychosis (G‐ACTp) delivered by trained staff and service-user experts, comprising four sessions over weeks 1-4 and two booster sessions at weeks 10 and 12.
Study: 32944971
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed G‐ACTp after 12 weeks).
Study: 34965950
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of aromatase inhibitors (AI)
Study: 32471908
Drug: Lixisenatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (20 μg subcutaneously daily)
Study: 35841410
Drug: RAM +
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAM + ERL (ramucirumab 10 mg/kg every 2 weeks with erlotinib 150 mg/day)
Study: 32725073
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid therapy
Study: 33970692
Drug: Early complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early complex decongestive therapy (CDT) started within 2 weeks after surgery for 30 minutes a day, for 2 weeks (5 days per week)
Study: 32330433
Drug: Prednisolone (1mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1mg/kg/day for 24 weeks, tapering from week 9)
Study: 34274496
Drug: Personalized antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antiplatelet therapy based on CYP2C19 genotype and urine 11‐dhTxB2 tests
Study: 34621052
Drug: Aramchol 600
Normalized name: Aramchol
DrugBank: Aramchol (DB11860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aramchol 600 mg
Study: 36199064
Drug: Metformin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin combined with dulaglutide (MET-DUL group)
Study: 32060972
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual breakthrough dose)
Study: 35701548
Drug: 94% ABV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 94% ABV alcohol (males: 1.0 ml/kg; females: 0.85 ml/kg)
Study: 32727577
Drug: esaxerenone 5
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: esaxerenone 5 mg/day with amlodipine 2.5 mg (Study 2)
Study: 32727577
Drug: esaxerenone 5
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: esaxerenone 5 mg/day with digoxin 0.25 mg/day (Study 3)
Study: 33837943
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of landfill leachate (LL) dose plus irrigation water (IW)
Study: 33837943
Drug: 200% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200% of landfill leachate (LL) dose plus irrigation water (IW)
Study: 35590308
Drug: LIA (Local
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA (Local Infiltration Analgesia) with ropivacaine, morphine, and betamethasone
Study: 34372930
Drug: Preventative intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventative intervention comprising risk communication using an online risk calculator, counselling style adapted from motivational interviewing, and 12 weekly telephone goal reinforcement calls (3 months)
Study: 34872927
Drug: Three-week language
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-week language therapy
Study: 33393711
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 2.5 g EP/kg diet
Study: 33393711
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 5.0 g EP/kg diet
Study: 33393711
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 7.5 g EP/kg diet
Study: 38479195
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion
Study: 35131532
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) vaginal gel 3 g every 3 days for 30 days
Study: 33652160
Drug: Vaginal isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal isosorbide mononitrate (40 mg, up to 3 doses)
Study: 36074385
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 μg/kg/h)
Study: 34101342
Drug: Ultrashort implants
Normalized name: UNDERPAD,BED ULTRASORB 23X24IN #MSC82100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrashort implants (5.5 mm)
Study: 34101342
Drug: Standard-length implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-length implants (10 mm)
Study: 39623757
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies
Study: 38502425
Drug: Ibuprofen alone
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen alone
Study: 39334205
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids
Study: 35758258
Drug: BMS-986120 75
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986120 75 mg
Study: 35758258
Drug: BMS-986120 180
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986120 180 mg
Study: 35758258
Drug: BMS-986120 ≥10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986120 ≥10 mg for 7 days
Study: 35758258
Drug: BMS-986120 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986120 (various doses)
Study: 32423618
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids
Study: 35554022
Drug: Nomogram based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram based on significant indices (age, tumor type, type of surgery, radiation therapy)
Study: 32449174
Drug: Ravulizumab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravulizumab (administered every 8 weeks)
Study: 32449174
Drug: Eculizumab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (administered every 2 weeks)
Study: 36217131
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg, once daily)
Study: 36217131
Drug: Budesonide/formoterol (160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (160/4.5 μg, one puff, twice daily)
Study: 32453453
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure reduction with intravenous nicardipine
Study: 34314516
Drug: CAPABLE program
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPABLE program (full-tested dose)
Study: 34314516
Drug: CAPABLE program
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPABLE program (decreased dose)
Study: 34778952
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment